Rupatadine improves nasal symptoms, quality of life (ESPRINT-15) and severity in a subanalysis of a cohort of Spanish allergic rhinitis patients

Journal of Investigational Allergology and Clinical Immunology

Volumn 21, Issue 3, 2011, Pages 229-235

  Valero, A ^a,b,c   Izquierdo, I ^d   Giralt, J ^d   Bartra, J ^a,b,c   del Cuvillo, A ^e   Mullol, J ^b,c,f  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Global Allergy and Asthma European Network   (Spain)

^d J Uriach y Compania   (Spain)

^e Clinica Dr Lobaton   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Allergic rhinitis; Oral H1 antihistamines; Quality of life; Rupatadine; Severity

Indexed keywords

RUPATADINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL PRURITUS; NOSE OBSTRUCTION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; RHINORRHEA; SPAIN; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ADULT; CYPROHEPTADINE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LONGITUDINAL STUDIES; MALE; NOSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL;

EID: 79955377405     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Inmunol. 2001;108(Suppl 5):S147-334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160.
3. Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT, El-Akkad T. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy. 2003;58(8):733-41.
4. Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J, Dykewicz MS, Fineman SM, Lee RE, Li JT, Portnoy JM, Schuller DE, Lang D, Tilles SA; Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immunology; Joint Council of Allergy, Asthma, and Immunology. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol. 2003;91(2):105-14.
5. Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specifi c measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52(3):187-92.
6. ESPRINT Study Group and Investigators. Development and validation of a new Spanish instrument to measure healthrelated quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. Value Health. 2007;10(6):466-77.
7. Valero A, Alonso J, Antépara I, Bar E, Colas C, del Cuvillo A, Ferrer M, Herdman M, Marti-Guadaño E, Monclus L, Navarro-Pulido AM, Sastre J, Izquierdo I, Mullol J. Health-related quality of life in allergic rhinitis: comparing the short form ESPRINT-15 and MiniRQLQ questionnaires. Allergy. 2007:62:1372-8.
8. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drug. 2007;67(3):457-74.
9. Guadaño EM, Serra Batlles J, Meseguer J, Castillo JA, de Molina M, Valero A, Picado C. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004;59(7):766-71.
10. Kowalski ML, Jukiewicz D, Kruszewski-J, Nowak D, Zietkowski Z, Spicakova M, Vernerova E, Seberova E, Klenha K, Izquierdo I. Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: A randomized, double-blind, controlled trial with loratadine and placebo. Therapy. 2009;6(3):417-25.
11. Fantin S, Maspero J, Bisbal C, Agache I, Donado E, García O, Arnáiz A, De la Cruz G, Pérez I, Izquierdo I. A 12-week placebocontrolled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008;63(7):924-31.
12. Stübner P, Horak F, Zieglmayer R, Arnaiz E, Leuratti C, Pérez I, Izquierdo I. Effects of rupatadine vs placebo on allergeninduced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2006;96(1):37-44.
13. Valero A, de la Torre F, Castillo JA, Rivas P, del Cuvillo A, Antepara I, Borja J, Donado E, Mola O, Izquierdo I. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009;32(1):33-42.
14. Valero A, Ferrer M, Sastre J, Navarro AM, Monclús L, Martí-Guadaño E, Herdman M, Dávila I, Del Cuvillo A, Colás C, Baró E, Antépara I, Alonso J, Mullol J. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol. 2007;120(2):359-65.
15. Bousquet JP, Combescure C, Klossek JM, Daures JP, Bousquet J. Changes in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Inmunol. 2009;123:1349-54.
16. Bousquet JP, Bachert C, Canonica GW, Csale TB, Mullol M, Klossek JM, Daures JP, Bousquet J. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126(3):666-8.e1-5.
17. V Valero A, Baró E, Sastre J, Navarro-Pulido AM, Izquierdo I, Martí-Guadaño E, Ferrer, Dávila I, del Cuvillo A, Colas C, Antepara I, Alonso J, Mullol J. Reference Values For Facilitating the Interpretation of the ESPRINT-15 Questionnaire (Spanish Version). J Investig Allergol Clin Immunol. 2009;19(5):396-403.
18. Valero A, M Ferrer, E Baró, J Sastre, AM Navarro, E Martí-Guadaño, I Dávila, A del Cuvillo, C Colás, I Antépara, J Alonso, O Mola, I Izquierdo, J Mullol. Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitis. Allergy. 2010;65:1609-13.
19. Bartra J, Mullol J, de Castellar R, del Cuvillo A, Navarro A, Torrents A, Mola O, Izquierdo I. Rupatadine improves disease severity and quality of life in a cohort of allergic rhinitis patients assessed using the ESPRINT-15 quality of life questionnaire. Allergy. 2009;64 (suppl 90):450-51.